MarketFriction

Vivo Bio Tech Ltd

NSE VIVOBIOT · BSE 511509 · Biotechnology
₹17.13 +0.41%
NSE close2026-10-01
52 week range15.51 - 20.94
Market cap₹36.4 Cr.
Price band 20% Delivery 79.5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales9.2612.8511.7610.1312.0412.2112.2912.5113.1113.5114.2014.28
Expenses4.406.486.395.776.456.677.277.037.698.029.759.23
Operating Profit4.866.375.374.365.595.545.025.485.425.494.455.05
OPM %52.48%49.57%45.66%43.04%46.43%45.37%40.85%43.80%41.34%40.64%31.34%35.36%
Other Income0.000.030.010.014.630.010.150.140.130.140.030.06
Interest2.092.221.521.922.061.841.681.501.471.401.481.24
Depreciation2.302.282.432.232.292.252.252.642.572.662.753.53
Profit before tax0.471.901.430.225.871.461.241.481.511.570.250.34
Tax %29.79%31.05%48.95%27.27%10.73%43.84%14.52%9.46%42.38%20.38%2,164.00%44.12%
Net Profit0.331.320.740.175.230.821.061.340.871.25-5.160.19
EPS in Rs0.220.890.500.113.510.510.620.670.390.57-2.330.09
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales28.5834.1347.0055.8355.3551.7851.3952.2345.4546.6753.3355.10
Expenses24.8726.5136.1146.3242.8833.9835.3030.3924.1926.1131.8234.69
Operating Profit3.717.6210.899.5112.4717.8016.0921.8421.2620.5621.5120.41
OPM %12.98%22.33%23.17%17.03%22.53%34.38%31.31%41.82%46.78%44.05%40.33%37.04%
Other Income0.890.400.130.010.050.080.100.040.044.80-0.160.36
Interest0.471.292.372.643.103.674.277.997.957.555.915.59
Depreciation3.353.904.645.065.175.597.459.279.299.0210.6311.51
Profit before tax0.782.834.011.824.258.624.474.624.068.794.813.67
Tax %-16.67%11.66%21.95%-23.08%-4.47%34.11%50.78%42.64%37.93%17.18%135.55%
Net Profit0.912.503.122.254.445.682.202.652.537.28-1.71-2.85
EPS in Rs0.972.673.171.823.454.231.541.781.704.24-0.77-1.28
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth6%1%1%12%
Compounded Profit Growth%%%-134%
Stock Price CAGR-9%-27%-24%-56%
Return on Equity6%2%1%-2%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital9.359.359.359.8512.3512.8913.4214.2614.9014.9017.1622.19
Reserves-0.180.713.229.4614.9220.1429.1132.8736.9739.5060.7470.97
Borrowings5.6916.9127.0625.1221.6824.3730.9667.4462.3973.0654.0267.38
Other Liabilities26.5718.6911.4915.086.376.296.037.918.779.6711.3117.89
Total Liabilities41.4345.6651.1259.5155.3263.6979.52122.48123.03137.13143.23178.43
Fixed Assets19.6923.5428.5727.6630.0134.9952.0595.1788.8780.3788.24123.03
CWIP0.070.042.963.940.070.150.320.871.909.2112.844.81
Investments0.000.000.000.000.000.000.000.000.000.000.0021.91
Other Assets21.6722.0819.5927.9125.2428.5527.1526.4432.2647.5542.1528.68
Total Assets41.4345.6651.1259.5155.3263.6979.52122.48123.03137.13143.23178.43
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity2.258.81-5.6611.11-0.788.6114.1816.6414.8315.5211.8334.93
Cash from Investing Activity-2.04-7.20-11.84-4.72-3.53-10.23-22.82-51.11-4.00-7.95-15.84-59.35
Cash from Financing Activity-0.89-0.326.83-3.430.722.098.7835.02-11.18-7.563.9024.57
Net Cash Flow-0.681.30-10.672.96-3.590.470.140.55-0.340.01-0.110.15
Free Cash Flow0.211.61-17.506.39-4.31-1.62-8.64-34.4710.837.57-4.01-2.51
CFO/OP81%234%-70%110%-13%68%96%118%77%80%65%166%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days88.4348.7982.0391.4854.9869.1151.3985.3786.5294.7687.9880.42
Inventory Days557.61169.23204.47289.48255.75451.13672.29312.99429.70831.44491.08365.90
Days Payable814.41362.93242.14304.36152.08166.7270.3774.0250.68100.4961.7888.00
Cash Conversion Cycle-168.38-144.9144.3676.61158.65353.52653.31324.35465.53825.71517.29358.32
Working Capital Days-353.72-131.2919.25-13.2836.2235.1528.768.1038.0963.76100.26-22.24
ROCE %4.67%5.98%12.37%15.18%9.55%13.82%18.78%9.29%11.02%9.94%9.04%7.74%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters42.08%42.08%42.08%42.08%42.08%38.89%40.85%39.07%35.17%35.17%35.43%30.62%
Public57.91%57.92%57.92%57.92%57.91%61.12%59.16%60.94%64.84%64.84%64.58%69.39%
No. of Shareholders13,00615,61518,97118,85219,54521,16721,93521,86521,64721,62221,42721,225

Fundamentals

Market Cap₹ 36.4 Cr.
Current Price₹ 16.4
Book Value₹ 42.0
ROCE7.74 %
ROE-2.24 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)12%
Compounded Profit Growth (TTM)-134%
Consolidated figures.
Valuation
Market capRs 38 Cr
Enterprise valueRs 104 Cr
Price to book0.41x
Price to sales0.69x
EV / EBITDA5.00x
EV / EBIT11.23x
EV / sales1.89x
Price to cash flow1.09x
Earnings yield-7.50%
P/E, 3-year average16.63x
P/B, 3-year average0.81x
P/E, 5-year average17.46x
P/B, 5-year average0.84x
Profitability
Operating margin (excl. other income)40.33%
Operating margin (incl. other income)40.03%
EBITDA margin37.70%
Pre-tax margin6.66%
Net profit margin-5.17%
Net margin, latest quarter1.33%
ROE-2.00%
ROCE7.33%
ROA-1.06%
ROE, 3-year average4.59%
ROCE, 3-year average9.96%
ROA, 3-year average2.02%
ROE, 5-year average4.81%
ROCE, 5-year average10.04%
ROA, 5-year average2.08%
ROIC (approx.)-2.07%
Tax rate135.55%
Other income / net worth-0.17%
Growth
Sales growth (latest year)14.27%
Profit growth (latest year)-123.49%
Sales CAGR, 3 years0.70%
Sales CAGR, 5 years0.59%
Sales growth QoQ0.56%
Sales growth YoY (latest quarter)14.15%
Profit growth YoY (latest quarter)-85.82%
Per share
EPS (TTM)Rs -1.28
EPS (latest year)Rs -0.77
EPS (latest quarter)Rs 0.09
EPS, 3-year averageRs 1.72
EPS, 5-year averageRs 1.70
Book value per shareRs 41.98
Sales per shareRs 24.83
Cash flow per shareRs 15.74
Free cash flow per shareRs -1.13
Efficiency
Asset turnover0.30x
Fixed asset turnover0.43x
Inventory turnover1.50x
Inventory days244 days
Debtor days80 days
Debtors turnover4.54x
Creditor days88 days
Cash conversion cycle358 days
Working capital days-22 days
Leverage
Total debtRs 67 Cr
Cash and bankRs 1 Cr
Net debtRs 66 Cr
Debt to equity0.72x
Net debt / EBITDA3.17x
Interest coverage1.66x
Owners' fund to total sources52.21%
Debt to assets37.76%
Cash flow
Cash from Operating Activity (latest year)Rs 35 Cr
Cash from Investing Activity (latest year)Rs -59 Cr
Cash from Financing Activity (latest year)Rs 25 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -3 Cr
FCFE (approx.: FCF + change in debt)Rs 11 Cr
Cash from ops / profit, 5 years7.24x
Sales to cash flow1.53x
Statement figures
Net sales (TTM)Rs 55 Cr
Net sales (latest year)Rs 53 Cr
Sales (latest quarter)Rs 14 Cr
Operating profit excl. other income (latest year)Rs 22 Cr
Operating profit (latest quarter)Rs 5 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 21 Cr
PBDT (TTM)Rs 15 Cr
Profit before tax (TTM)Rs 4 Cr
Tax (latest year)Rs 7 Cr
Net profit (TTM)Rs -3 Cr
Net profit (latest year)Rs -2 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 12 Cr
Depreciation (latest quarter)Rs 4 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 12 Cr
Total expenditure (latest year)Rs 32 Cr
Total income (latest year)Rs 53 Cr
Share capitalRs 22 Cr
ReservesRs 71 Cr
Shareholders' fundsRs 93 Cr
Total assetsRs 178 Cr
Net blockRs 123 Cr
Capital work in progressRs 5 Cr
InvestmentsRs 22 Cr
ReceivablesRs 12 Cr
InventoryRs 8 Cr
Other liabilitiesRs 18 Cr
Shares outstanding (crore)2.22
Ownership
Promoter holding30.62% (-8.45 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 0.41 is the lowest in 9.4 years (median 2.04).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodVIVOBIOTNifty 50Difference
1 week+6.5%-2.8% +9.3 pts
1 month-6.4%-6.8% +0.4 pts
3 years-52.9%+14.2% -67.0 pts
5 years-79.1%+27.9% -107.0 pts

Red flags

F-score 2 of 8
lookShare dilution Share count up 29% in a year
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹14 Cr +14.1% vs Jun 2025. Net profit ₹0 Cr -85.8%.
Against our estimate for Jun 2026: sales +0.9%, profit -83.1% in line. Our estimate for Sep 2026: sales Rs 15 Cr, profit Rs 1 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Anthem Biosciences Ltd48,99682.630.4 %
Advanced Enzyme Technologies Ltd3,15220.014.0 %
CCME Global Ltd208-2.92 %
Shree Ganesh Biotech India Ltd191.31 %
Genomic Valley Biotech Ltd98861.02 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 days

Quick answers

What is the market cap of Vivo Bio Tech Ltd?

Vivo Bio Tech Ltd (VIVOBIOT) has a market capitalisation of Rs 36.4 Cr. at the 2026-10-01 close.

What were Vivo Bio Tech Ltd's latest quarterly results?

In the Jun 2026 quarter, Vivo Bio Tech Ltd sales was Rs 14 Cr (+14.1% vs Jun 2025) and net profit was Rs 0 Cr.

What is the 52-week high and low of Vivo Bio Tech Ltd?

The 52-week high is Rs 20.94 and the 52-week low is Rs 15.51.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03